BIVI - HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys Firm Investigating Possible Securities Law Violations | Benzinga

SAN FRANCISCO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/BIVI
Contact An Attorney Now: BIVI@hbsslaw.com
844-916-0895

BioVie Inc. (BIVI) Investigation:

The investigation focuses on the propriety of BioVie's disclosures concerning its adherence to Good Clinical Practice ("GCP") and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer's disease drug.

On Sep. 26, 2023, BioVie announced completion of the last treatment visit in its Phase 3 clinical trial of NE3107.

But on Nov. 8, 2023, BioVie shocked investors when it revealed that "during routine monitoring of blinded data from our Phase 3 study of […] NE3107, we uncovered what appears to be potential scientific misconduct and significant non-compliance with GCPs and regulations at six sites[]" and ...

BIVI) Investors with Substantial Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations>Full story available on Benzinga.com